17,261 trials
Relapse/Refractory Multiple Myeloma
Primary: Percentage of Participants With Near Complete Response (nCR)/ Complete Response (CR) Rate — 48.4 Percentage of participants — p=< 0.0001
Cognition Disorder · Attention Deficit Disorder · Traumatic Brain Injury
Primary: Perceptual Organization and Processing Speed Index — 89 score on a scale
Primary Open Angle Glaucoma or Ocular Hypertension
Primary: Mean Diurnal IOP (Intraocular Pressure) (mmHg) — 14.35; 14.33; 17.32 mmHg
Myocardial Infarction · Percutaneous Coronary Intervention
Primary: Comparisons of Vasodilator-stimulated Phosphoprotein (VASP) Phosphorylation Platelet Reactivity Index (PRI) — 71.0; 57.5; 62.4; 46.9 % of PRI
Pancreatic Adenocarcinoma · Resectable Pancreatic Carcinoma · Stage I Pancreatic Cancer
Primary: Number of Participants With Progressive Disease, — 2 Participants
Rhinosinusitis
Primary: Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks. — 59.3; 52.9; 45.4; 51.8 units on a scale
Moderate or Severe Opioid Use Disorder
Primary: Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w…
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score — 22.9; 22.0; 20.3; 20.4 score on a scale — p=0.0390
Chronic Obstructive Pulmonary Disease, COPD
Primary: Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline — 1708.0; 1877.3; 1881.8; 1883.6 mL — p=<0.001
Type 1 Diabetes Mellitus
Primary: Effect of Anakinra Treatment on PBMC Gene Expression for Patients — 0 probe sets
HER2-positive Newly Diagnosed, Primary Breast Cancer
Primary: Pathological Complete Response (pCR) Rate at the Time of Surgery - All Participants — 32.0; 40.0 Percentage of participants — p=0.811
Parkinson's Disease
Primary: Delta Medio-lateral Postural Sway Range (Foam) — 0.007; -0.004 m/s^2
HIV Infections
Primary: CD4+ Cell Count Change Between Basal and Week 16 of Additive Treatment — 153.2 CD4+ T-cell count/uL
Untreated Adult Acute Myeloid Leukemia
Primary: Proportion of Complete Responses (CR or CRi) During Induction Therapy — 0.618 proportion of participants
Bacterial Infections
Primary: Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator — 94.6; 90.1; 91.1…